Company overview
Novo Nordisk Asia Pacific Pte Ltd
UEN
199705347C
Name
Novo Nordisk Asia Pacific Pte Ltd
Former names
Novo Nordisk Health Care (Asia Pacific)
Entity type
Local Company
UEN Issue Date
1 August 1997
Secondary SSIC Code
70201
Status
Dissolved - Members Voluntary Winding Up
Incorporation date
1 August 1997
Address
238A, THOMSON ROAD, #16-06/08, NOVENA SQUARE
Postal Code
307684
Country
Singapore
Primary goods traded
- 💉65.1% — Medicaments (300431)
- 14.9% — Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues (293712)
- 11.0% — Medicaments (300439)
- 💊8.7% — Medicaments (300490)
- 0.3% — Medical, surgical instruments and appliances (901832)
Main Trading Partners
| Partner | Type | Total Value | Percentage |
|---|---|---|---|
| PT Beta Pharmacon | buyer | $348,291,417 | 25.51% |
| PT Ferron Par Pharmaceuticals | buyer | $64,527,156 | 4.73% |
Loading chart...
Loading chart...
Trade Data
| Data Source | HS Code | Description | Buyer | Buyer Country | Seller | Seller Country | ||
|---|---|---|---|---|---|---|---|---|
| 16 September 2025 | PH | 30043100000 | Ozempic 1Mg 1Pc. With Nf Plus 4Pcs. - 123,440 Ea | Novo Nordisk Pharmaceuticals Philippines | PH | Novo Nordisk As | $8,845,820.36 | |
| 26 April 2022 | RU | 3004900002 | Medicines Not Containing Antibiotics, Hormones, Alkaloids, Vitamins, Iodine Or Iodine Compounds: Saxendar (Liraglutide) Solution For Subcutaneous Introduction 6 Mg / Ml (Cartridge In Syringe-Pen) 3 Mlh3 (Pack. Cart.) - 51360 Pack., Series Do, Mp5b03 | Novo Nordisk Llc | RU | Novo Nordisk As | $7,485,030.00 | |
| 20 July 2022 | RU | 3004310000 | Medicines For Medical Use Packed In Dosage Forms Not Packed For Retail, Not For Veterinary: | Novo Nordisk Llc | RU | Novo Nordisk As | $6,150,840.00 | |
| 24 November 2022 | RU | 3004310000 | Medicines For Medical Use Packed In Dosage Forms Not Packed For Retail, Not For Veterinary: | Novo Nordisk Llc | RU | Novo Nordisk As | $5,837,190.00 | |
| 12 March 2018 | RU | 2937120000 | Insulin And Its Salts. Pharmaceutical Substance. Is Intended For The Production Of Drugs For Medical Use (And Exactly: Production Of A Ready Dosage Form Of Solutions And Suspensions For Subcutaneous And Intravenous Administration, Insulin De | Novo Nordisk Llc | Novo Nordisk As | $5,708,443.90 | ||
| 27 March 2025 | PH | 30043100000 | Ozempic 1.5 Ml 0.5 Mg With Nf Plus 4 Pcs - 79,715 Ea | Novo Nordisk Pharmaceuticals Philippines | PH | Novo Nordisk As | $5,687,858.45 | |
| 21 October 2022 | RU | 3004310000 | Medicines For Medical Use Packed In Dosage Forms Not Packed For Retail, Not For Veterinary: | Novo Nordisk Llc | RU | Novo Nordisk As | $5,532,080.00 | |
| 16 July 2018 | RU | 2937120000 | Insulin And Its Salts. Pharmaceutical Substance. Intended For Production Of Medicinal Products For Medical Use (And Exactly: Production Of A Ready Dosage Form Of Solutions And Suspensions For Subcutaneous And Intravenous Administration, Primary Package) Not For Retail, Does Not Contain Alcohol, Not For Veterinary Medicine: Insulin Aspart, Crystalline Powder. Series Gq1ahp046. Valid Until 14.02.2022 Register Number: Фс-000844 Dated 05.22.17 Insulin Detemir, Crystalline Powder. Series Gdfdhp217. Valid Until 08/20/2022 Register Number: Фс-001313 Of 01/14/16 Insulin Detemir, Crystalline Powder. Series Gdfdhp218. Valid Until 21.08.2022 Register Number: Фс-001313 Of 14.01.16 Insulin Detemir, Crystalline Powder. Series Gdfdhp227. Valid Until 08/28/2022 Register Number: Фс-001313 Of 01/14/16 | Novo Nordisk Llc | RU | Novo Nordisk As | $5,148,870.39 | |
| 25 August 2021 | RU | 2937120000 | Insulin And Its Salts.â Pharmaceutical Substance.â Prepared For The Production Of Medicinal Products For Medical Use | Novo Nordisk Llc | RU | Novo Nordisk As | $4,871,320.00 | |
| 25 August 2020 | RU | 2937120000 | Insulin And Its Salts. Pharmaceutical Substance. Intended For The Production Of Drugs For Medical Use (And That Is: Production Of A Ready Dosage Form Of Solutions And Suspensions For Subcutaneous And Intravenous Administration | Novo Nordisk Llc | RU | Novo Nordisk As | $4,860,521.05 |
0 of 20 row(s) selected.